Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
McKinsey
Express Scripts
Dow

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208685

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 208685 describes EMFLAZA, which is a drug marketed by Ptc Therap and is included in two NDAs. It is available from two suppliers. Additional details are available on the EMFLAZA profile page.

The generic ingredient in EMFLAZA is deflazacort. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the deflazacort profile page.
Summary for 208685
Tradename:EMFLAZA
Applicant:Ptc Therap
Ingredient:deflazacort
Patents:0
Generic Entry Opportunity Date for 208685
Generic Entry Date for 208685*:
Constraining patent/regulatory exclusivity:
TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
Dosage:
SUSPENSION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208685
Suppliers and Packaging for NDA: 208685
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EMFLAZA deflazacort SUSPENSION;ORAL 208685 NDA Marathon Pharmaceuticals, LLC 42998-505 42998-505-21 13 mL in 1 BOTTLE (42998-505-21)
EMFLAZA deflazacort SUSPENSION;ORAL 208685 NDA PTC Therapeutics, Inc. 52856-505 52856-505-21 13 mL in 1 BOTTLE (52856-505-21)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION;ORALStrength22.75MG/ML
Approval Date:Feb 9, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 9, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Jun 7, 2026
Regulatory Exclusivity Use:TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
Regulatory Exclusivity Expiration:Feb 9, 2024
Regulatory Exclusivity Use:TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.